Teva Ordered to Produce Pharmacovigilance Discovery in Purienthol Case

SAN FRANCISCO – A California federal judge has ordered Teva Pharmaceuticals Corp. to produce discovery regarding its pharmacovigilance beyond 2004 in a case in which plaintiffs allege their son’s hepatosplenic T-cell lymphoma was caused by combining Purinethol with Remicade or Humira.

On April 22, Magistrate Judge Jacqueline S. Corley of the U.S. District Court for the Northern District of California ruled that Teva should produce the discovery covering the time period from when plaintiffs’ son was first treated with the drug until he was diagnosed with HSTCL in 2007, even though he had stopped taking Teva’s brand name version in …